Liepajas Regionala Slimnica SIA
- Address
- lock Available on a paid plan
Neoplasms (Cancer)
The oncology department at Liepajas Regionala Slimnica SIA is conducting trials that target advanced tumors and cancers with specific genetic profiles. Researchers are evaluating new combination therapies to improve response rates and overall survival for patients with HRR‑mutated or HRD‑positive disease.
- Combination of targeted agents with immunotherapy
- Assessment of objective response using RECIST criteria
- Long‑term survival outcomes in solid tumor patients
These studies aim to establish more effective treatment options for individuals facing aggressive cancers.
Cardiovascular Diseases
Trials at the site focus on atrial fibrillation and related thromboembolic conditions, testing novel anticoagulants to prevent stroke and systemic embolism while minimizing bleeding risk. The research also includes strategies for managing blood clot formation after orthopedic surgery.
- Comparison of new oral anticoagulants with standard therapy
- Prevention of venous thromboembolism post‑knee replacement
- Evaluation of major bleeding events and overall safety
The goal is to provide safer, more effective options for patients at high risk of cardiovascular events.
Bacterial Infections and Mycoses
The hospital is investigating treatments for severe community‑acquired bacterial pneumonia, exploring innovative agents that may enhance clinical recovery and reduce reliance on traditional antibiotics.
- Effectiveness of adjunctive therapy in severe pneumonia
- Safety and tolerability compared with placebo
- Impact on hospitalization duration and patient outcomes
This research seeks to improve management of serious respiratory infections.
Digestive System Diseases
Studies are underway for individuals with moderately to severely active ulcerative colitis, testing new oral compounds aimed at achieving clinical remission and improving quality of life.
- Induction of remission at 12 weeks
- Assessment of mucosal healing
- Safety profile in a chronic inflammatory condition
The purpose is to expand therapeutic choices for patients with challenging inflammatory bowel disease.
Hemic and Lymphatic Diseases
Research includes prevention of blood clots in surgical settings, focusing on venous thromboembolism after knee arthroplasty and other high‑risk procedures.
- Evaluation of clot‑preventing agents versus standard anticoagulation
- Measurement of clot incidence and related complications
- Monitoring of bleeding risk and overall patient safety
These investigations aim to reduce postoperative complications and enhance recovery.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Liepajas Regionala Slimnica SIA
lock Showing 1 of 32 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 4 | Unknown | 2022-08-10 | 2025-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.